Bioreactors Market Report 2025

This Bioreactors market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The bioreactors market size has grown rapidly in recent years. It will grow from $9.22 billion in 2024 to $10.64 billion in 2025 at a compound annual growth rate (CAGR) of 15.2%. The growth observed during the historic period can be attributed to several factors, including the increasing demand for biopharmaceuticals, the rise in cell and gene therapy research, a growing focus on personalized medicine, the adoption of single-use bioreactor technology, and the need for more efficient manufacturing processes.

The bioreactors market size is expected to see rapid growth in the next few years. It will grow to $18.58 billion in 2029 at a compound annual growth rate (CAGR) of 14.9%. The growth anticipated during the forecast period can be attributed to factors such as increased investment in biotechnology research, the rising prevalence of chronic diseases, growing demand for vaccines and therapeutic proteins, enhanced regulatory support for biomanufacturing, and the increasing use of advanced therapies. Key trends for this period include advancements in biotechnology, improvements in automation and control systems, growth in bioprocess development, enhancements in manufacturing efficiency, and a rising need for scalable production solutions.

The rising demand for biopharmaceuticals is anticipated to drive the growth of the bioreactors market in the coming years. Biopharmaceuticals are therapeutic products derived from biological sources, including proteins, cells, and living organisms, used to prevent, treat, or manage various diseases. This growing demand is fueled by advancements in medical research, the rise of personalized medicine, and the need for innovative treatments, which contribute to improved healthcare outcomes globally. Bioreactors play a crucial role in the biopharmaceutical sector by enabling the efficient and scalable production of therapeutic products. They ensure consistent quality, lower production costs, and support the development of innovative, life-changing medicines. For example, in May 2024, data from Pharmaceutical Research and Manufacturers of America, a U.S.-based trade association, revealed that the U.S. biopharmaceutical industry generated over $1.65 trillion in total output in 2022, including $800 billion from direct production and another $800 billion from suppliers and related sectors, representing 3.6% of the U.S. economy. Consequently, the increasing demand for biopharmaceuticals is fueling the growth of the bioreactors market.

Leading companies in the bioreactors market are focusing on creating innovative solutions, such as fixed-bed bioreactors, to accommodate the growth of more complex biological cultures. Fixed-bed bioreactors utilize a solid support structure, often made from porous materials such as beads, fibers, or granules, to which biological organisms adhere. This design improves mass transfer, reduces shear stress, and offers better control over biological processes. For example, in October 2024, Univercells Technologies, a biotechnology company based in Belgium, introduced the Scale-X Nexo bioreactor. This advanced bioreactor, with a 0.5 m² growth surface, is tailored to optimize cell culture process development, delivering significant advantages for biopharmaceutical companies and research organizations. The Scale-X Nexo enables seamless scalability to larger models, reduces media and reagent usage, and can cut operational costs by up to 60% compared to conventional entry-level bioreactors. Furthermore, it integrates with Skaia Vision application software, enhancing productivity by providing accurate cell count estimates without requiring direct sampling.

In December 2022, MilliporeSigma, a U.S.-based life sciences organization, acquired Erbi Biosystems Inc. for an undisclosed sum. This acquisition aims to enhance MilliporeSigma's upstream portfolio for therapeutic proteins by incorporating Erbi Biosystems' advanced 2 ml micro-bioreactor technology. The integration supports scalable, automated perfusion cell culture processes and accelerates the creation of life-enhancing therapeutics. Erbi Biosystems Inc., a U.S.-based biotechnology firm, specializes in the development of micro-bioreactor systems for optimizing cell culture and bioprocesses.

Major players in the bioreactors market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE HealthCare Technologies Inc., Cytiva Bioscience Holding Ltd., Sartorius AG, Cellexus Ltd., Getinge AB, Eppendorf AG, ZETA Holding, Pierre Guerin, Broadley-James Corporation, PBS Biotech Inc., TAP Biosystems, Solida Biotech GmBH, BBI-Biotech GmbH, HiTec Zang GmbH, Xiamen Ollital Technology Co. Ltd., Bioengineering AG, Infors AG, Univercells Technologies SA, CerCell A/S, Bailun Biotechnology Co. Ltd., BioNet, and Shanghai Ritai Medicine Equipment Project Co. Ltd.

North America was the largest region in the bioreactors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bioreactors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bioreactors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A bioreactor is a specialized system designed to maintain optimal conditions for biological processes, supporting the growth and function of cells, microorganisms, or enzymes. It ensures suitable environmental factors, including temperature, pH, oxygen, and nutrient supply, to enable desired biochemical reactions. Bioreactors are commonly utilized in industries such as pharmaceuticals, food production, and wastewater treatment.

The primary types of bioprocesses used in bioreactors are batch, fed-batch, and continuous. Bioreactors can support both batch and fed-batch processes, offering flexibility in optimizing production based on the complexity of the product and required yields. They are used with various cell types, including mammalian, bacterial, and yeast cells, and incorporate different control methods, such as manual and automated systems. Bioreactors are employed in applications ranging from lab-scale and pilot-scale production to full-scale production, serving end users such as research and development (R&D) organizations, biopharmaceutical manufacturers, and contract manufacturing organizations (CMOs).

The bioreactors market research report is one of a series of new reports that provides bioreactors market statistics, including the bioreactors industry global market size, regional shares, competitors with the bioreactors market share, detailed bioreactors market segments, market trends, and opportunities, and any further data you may need to thrive in the bioreactors industry. These bioreactors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bioreactors market consists of sales of stirred-tank bioreactors (STRs), airlift bioreactors, bubble column bioreactors, and packed-bed bioreactors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.